← Back to patent-cliff list
DAT-2645
Tier C — Watch / tradeDAT-2645
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PARG
Indications (approved)：Ovarian cancer, Solid tumour, Colorectal cancer, Prostate cancer, Breast cancer, Gastric cancer, Pancreatic cancer, Endometrial cancer
Regional status
US
Phase I
2024-06-22
EU
-
China
Phase II
2026-05-28
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of DAT-2645?
Approved indications include: Ovarian cancer, Solid tumour, Colorectal cancer, Prostate cancer, Breast cancer, Gastric cancer, Pancreatic cancer, Endometrial cancer.
When does the DAT-2645 patent expire?
No public expiry year is available for DAT-2645 yet; this page updates once verified.
How do I get a quote for DAT-2645 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29